European Commission Approves Incyte's Povofortay for Hidradenitis Suppurativa
The European Commission has granted marketing authorization to Incyte (INCY) for its once-daily oral medication, Povofortay (povorcitinib). The drug is indicated for the treatment of hidradenitis suppurativa, a chronic and debilitating inflammatory skin condition also known as acne inversa. As a JAK inhibitor, Povofortay will be made available in two dosage strengths: 45 mg and 75 mg. This regulatory approval marks a significant milestone for Incyte's immunology pipeline within the European market.

Tickers: $INCY